Clinical trials: Dermatitis Eczema
Moderate-to-severe Atopic Dermatitis
The Study of CM310 in Patients With Atopic Dermatitis
This is an open, multicenter, extension study evaluating the safety and efficacy of CM310 for long-term treatment in patients with atopic dermatitis The primary objective is to assess the long-term safety of CM310 administered in…
- Trial name
- NCT04893707
- Testing
- CM310
- Where
- China
- Volunteers
- 127 people
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis
Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102
The principal aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 29102 is administered cutaneously as single and multiple doses to healthy subjects.
- Trial name
- NCT01423656
- Testing
- LEO 29102
- Where
- United Kingdom
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Atopic Dermatitis
Evaluation of an Adapted Formula on Atopic Dermatitis.
The aim of this study is to show the efficiency of a new infant formula containing fiber on the management of moderate to severe atopic dermatitis.
- Trial name
- NCT05318300
- Testing
- tested formula with fiber, Control
- Where
- 3 sites in Belgium, France
- Volunteers
- 126 people
- Sponsor
- United Pharmaceuticals
Atopic Dermatitis
Use of a Mobile Health App in Managing Pediatric Atopic Dermatitis
A randomized controlled study in children with AD, divided into three groups: a control group without access to the app, an experimental observational group with the app, and an experimental interventional group with potential…
- Trial name
- NCT06412094
- Testing
- Standard care, Access to the "AtopicApp" mobile application, Virtual oversight through the AtopicApp
- Where
- Russia
- Volunteers
- 66 people
- Sponsor
- Avanta Trading Ltd.
Atopic Dermatitis
Assessment of Efficacy of the Consumption of a Heat-treated Lactobacillus Paracasei (GM080) on Atopic Dermatitis
The primary objective of this trial is to assess the efficacy of the consumption of heat-treated Lactobacillus paracasei (GM080) on atopic dermatitis as compared to a placebo treatment.
- Trial name
- NCT02103972
- Testing
- GM080, Maltodextrin
- Where
- 6 sites in Taiwan
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Atopic Dermatitis
Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).
Primary objective: To evaluate the efficacy of subcutaneous (SC) administration of tralokinumab compared with placebo in treating adolescent subjects (age 12 to <18 years) with moderate-to-severe AD.
- Trial name
- NCT03526861
- Testing
- Tralokinumab
- Where
- 87 sites in United States, Australia and 8 more
- Volunteers
- 301 people
- Sponsor
- LEO Pharma
Dermatitis, Atopic
Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
A long-term observational registry in patients with atopic dermatitis (AD) initiating treatment with DUPIXENT® (dupilumab)
- Trial name
- PROSE (NCT03428646)
- Testing
- Dupilumab
- Where
- 99 sites in United States, Canada
- Volunteers
- 858 people
- Sponsor
- Regeneron Pharmaceuticals
Nummular Eczema
A Study of Lebrikizumab in Adults With Nummular Eczema
The main aim of the study is to evaluate the efficacy, safety, and tolerability of lebrikizumab treatment in adult participants with Nummular Eczema (NE) who are not adequately controlled with Topical corticosteroids (TCS) or…
- Trial name
- LUMINE (NCT07542483)
- Testing
- Lebrikizumab
- Where
- Germany
- Volunteers
- 270 people
- Sponsor
- Almirall, S.A.
Atopic Dermatitis
Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis
The objective of this pilot double-blind study was to evaluate the efficacy and the safety of Broncho-Vaxom 1 capsule (3.5 mg) per day for 9 months compared to placebo on the evolution of the disease in children suffering from…
- Trial name
- NCT03047954
- Testing
- Broncho-Vaxom
- Volunteers
- 179 people
- Sponsor
- Vifor Pharma
Atopic Dermatitis
Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%
Randomized, double-blind, parallel group, placebo-controlled, multicenter, efficacy and safety study in subjects with mild to moderate atopic dermatitis.
- Trial name
- C012013 (NCT02031445)
- Testing
- MRX-6
- Where
- 5 sites in Israel
- Volunteers
- 73 people
- Sponsor
- Celsus Therapeutics PLC
Pregnancy Related, Atopic Dermatitis
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
This observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (MCM)s among infants of women exposed to ruxolitinib cream during…
- Trial name
- OPERA-1 (NCT06259669)
- Testing
- Ruxolitinib Cream
- Where
- United States
- Volunteers
- 958 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis (AD)
A Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis
This is a Phase 2 research study testing an investigational topical cream called JYP0066 for the treatment of mild-to-moderate atopic dermatitis (eczema) in teenagers (12-17 years old) and adults.
- Trial name
- NCT07843290
- Testing
- JYP0066 4% topical cream, 3% JYP0066 topical cream, 2% JYP0066 topical cream
- Volunteers
- 160 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Pruritus in Patients With Atopic Dermatitis
Safety and Efficacy of DNK333 in Atopic Dermatitis Patients
This study will assess the safety and efficacy of DNK333 in patients with atopic dermatitis suffering from pruritus, who require systemic treatment of the disease.
- Trial name
- NCT01033097
- Testing
- DNK333 5 mg, DNK333 25 mg, DNK333 100 mg
- Where
- 5 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
A Study Evaluating TRIV-509 in Atopic Dermatitis
The goal of this interventional study is to learn if TRIV-509 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-509.
- Trial name
- NCT07167758
- Testing
- TRIV-509
- Where
- 32 sites in United States, Bulgaria and 5 more
- Volunteers
- 95 people
- Sponsor
- Triveni Bio
Pruritus, Atopic Dermatitis
Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis
Kappa-opioid receptors mediate the sensation of itch in animals and humans. Asimadoline is an orally active, selective kappa-opioid receptor agonist and has demonstrated efficacy in several preclinical pruritus models.
- Trial name
- NCT02475447
- Testing
- Asimadoline
- Where
- 22 sites in United States
- Volunteers
- 249 people
- Sponsor
- Tioga Pharmaceuticals
Atopic Dermatitis
Study of 0417 Ointment in the Treatment of Atopic Dermatitis
The aim of this trial is to assess the efficacy of 0417 Ointment in the Treatment of Atopic Dermatitis. Treatment medication will be administered as follows: Apply a thin layer of ointment to affected skin areas twice daily and…
- Trial name
- NCT01139450
- Testing
- 0417, Vehicle of 0417 test product, Tacrolimus Ointment 0.03%
- Where
- United States
- Volunteers
- 899 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Atopic Dermatitis
Open-label Study of Dupilumab in Patients With Atopic Dermatitis
The primary objective is to assess the long-term safety of dupilumab administered in adult participants with atopic dermatitis (AD).
- Trial name
- NCT01949311
- Testing
- Dupilumab
- Where
- 432 sites in United States, Australia and 26 more
- Volunteers
- 2,733 people
- Sponsor
- Regeneron Pharmaceuticals
Eczema
Blue Light for Treating Eczema
Monocenter, randomized, intraindividual, open label, exploratory study comparing 4 weeks of treatment with 453nm blue light with no treatment in patients with Eczema.
- Trial name
- NCT02002871
- Testing
- PSO-CT02 device
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Philips Electronics Nederland BV
Allergic Rhinitis, Allergic Conjunctivitis
Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis
This first-in-human (FIH) study is a randomized, double-blinded, placebo-controlled, ascending dose study to investigate the safety, tolerability, and pharmacokinetics of XmAb7195 in adult healthy volunteers and in adult subjects…
- Conditions
- Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis
- Trial name
- NCT02148744
- Testing
- XmAb7195
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Xencor, Inc.
Atopic Dermatitis
A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis
Participants who meet eligibility criteria will be randomized in a 1:1:1 ratio to receive a twice daily oral LNK01001 dose A or LNK01001 dose B or matching placebo for 12 weeks.
- Trial name
- NCT06085521
- Testing
- LNK01001 Dose A, LNK01001 Dose B
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Lynk Pharmaceuticals Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.